DBV Technologies (NASDAQ:DBVT) Upgraded to Strong-Buy at Lifesci Capital

DBV Technologies (NASDAQ:DBVT - Get Free Report) was upgraded by stock analysts at Lifesci Capital to a "strong-buy" rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other equities analysts have also commented on DBVT. Citigroup reiterated an "outperform" rating on shares of DBV Technologies in a report on Tuesday, May 27th. JMP Securities reaffirmed a "market outperform" rating and set a $21.00 target price on shares of DBV Technologies in a research report on Thursday. HC Wainwright increased their price target on DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a report on Monday, May 5th. The Goldman Sachs Group upgraded DBV Technologies to a "sell" rating and set a $7.25 price objective for the company in a research note on Thursday, May 29th. Finally, Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, DBV Technologies presently has a consensus rating of "Moderate Buy" and an average target price of $14.75.

DBV Technologies Stock Performance

DBV Technologies stock opened at $9.21 on Thursday. The firm has a market capitalization of $252.26 million, a PE ratio of -1.87 and a beta of -0.63. DBV Technologies has a one year low of $2.20 and a one year high of $12.78. The stock's 50 day moving average price is $9.22 and its 200 day moving average price is $6.24.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 278.24% and a negative net margin of 3,249.99%. On average, analysts forecast that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.